Freenome uses artificial intelligence to conduct cancer screenings and diagnostic tests to spot signs of cancer earlier than possible with traditional testing methods. It uses non-invasive blood tests to recognize disease-associated patterns. The company’s solution has trained on cancer-positive blood samples, which enables it to detect problems using specific biomarkers. Freenome uses AI to conduct cancer screenings and diagnostic tests. Using non-invasive blood tests, the company’s AI technology recognizes disease-associated patterns, providing earlier cancer detection and better treatment options.
The company was founded in 2016. The company specializes in developing high-quality diagnostic tests for the early detection of cancer using multi-omics technology. Freenome has received significant funding from investors such as Roche, which made an investment of $290 million in 2022.
Some additional information about Freenome are:
- The company’s mission is to empower everyone to prevent, detect, and treat disease by developing high-quality diagnostic tests.
- The company’s CEO is Mike Nolan.
- The company’s name is derived from the word “freenom”, which means “a name for everyone” and also refers to a fast and anonymous public DNS resolver service provided by Freenom, a different entity.